Core Viewpoint - The company Zhifei Biological (300122.SZ) has announced that its subsidiary, Chongqing Chen'an Biological Pharmaceutical Co., Ltd., has initiated Phase I clinical trials for the CA111 injection in Zhejiang Province [1] Group 1: Product Development - The CA111 injection is a dual agonist targeting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors [1] - GIP is a 42-amino acid gastrointestinal regulatory peptide that stimulates insulin secretion from pancreatic beta cells in the presence of glucose and protects these cells, playing a physiological role in glucose homeostasis [1] - GLP-1 is a 37-amino acid peptide that stimulates insulin secretion, protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying, and food intake, thereby controlling blood sugar and body weight [1] - The dual receptor agonist approach of GIP and GLP-1 can achieve synergistic effects, leading to better glucose-lowering and weight loss outcomes compared to single-target drugs, while effectively reducing side effects [1]

Core Viewpoint - The announcement highlights that Zhifei Biological's subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of CA111 injection in overweight or obese adults [1] Group 1: Product Development - CA111 injection is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors [1] - GIP is a gastrointestinal regulatory peptide consisting of 42 amino acids, which stimulates insulin secretion from pancreatic beta cells and protects these cells, playing a physiological role in glucose homeostasis [1] - GLP-1 is a peptide of 37 amino acids that stimulates insulin secretion, protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying, and food intake, thereby controlling blood sugar and body weight [1] - The dual receptor agonist mechanism of GIP and GLP-1 can achieve synergistic effects for better glucose-lowering and weight loss outcomes [1]

Core Viewpoint - The announcement highlights that Zhifei Biological's subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of CA111 injection in overweight or obese adults [1] Group 1: Product Development - CA111 injection is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors [1] - GIP is a 42-amino acid gastrointestinal regulatory peptide that stimulates insulin secretion from pancreatic beta cells in the presence of glucose and protects these cells, playing a physiological role in glucose homeostasis [1] - GLP-1 is a 37-amino acid peptide that stimulates insulin secretion, protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying, and food intake, thereby controlling blood sugar and body weight [1] - The dual receptor agonist mechanism of GIP and GLP-1 can achieve synergistic effects for better glucose-lowering and weight loss outcomes [1]